CC:0
CC:0

EXPERT REACTION: Trial results for potential HIV vaccine show promise

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.

People: This is a study based on research using people.

Following World HIV Day, a Phase 1 clinical trial has provided promising results for a HIV vaccine, say international researchers. They say this vaccine, tested in humans, elicits the creation of broadly neutralising antibodies (bnAbs), which can recognise the globally diverse strains of HIV, and could protect against infection. They say this trial induced bnAb-precursor responses in 26 of the 27 vaccine recipients (97%).

Journal/conference: Science

Link to research (DOI): 10.1126/science.add6502

Organisation/s: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA

Funder: This work was supported by the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVIMC INV-007368 to D.M. and G.D.T.; CCVIMC INV-007371 to R.A.K., A.B.M., and M.J.M.; VISC INV- 008017 and INV-032929 to A.C.d.; VxPDC INV-008352 and INV- 007375 to IAVI; and NAC INV-007522 and INV-008813 to W.R.S.); IAVI (including IAVI 167627819 to M.J.M., IAVI A08031 research collaboration agreement with Karolinska Intitutet to G.B.K.H., and other support to W.R.S.); the IAVI Neutralizing Antibody Center (NAC) to W.R.S.; National Institute of Allergy and Infectious Diseases (NIAID) P01 AI094419 (HIVRAD Optimizing HIV immunogen-BCR interactions for vaccine development”) (to W.R.S.); UM1 Al100663 (Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery) and UM1 AI144462 (Scripps Consortium for HIV/AIDS Vaccine Development) (to W.R.S. and M.J.M.); and UM1AI069481 (Seattle-Lausanne CTU), U19AI128914 (HIPC), and UM1AI068618 (HVTN LC) to M.J.M. This work was also supported by the Swedish Research Council (grant 2017-00968 to G.B.K.H.) and by the Ragon Institute of MGH, MIT, and Harvard (to W.R.S.).

Media release

From: AAAS

Germline-targeting HIV vaccine induces broadly neutralizing antibody precursors in humans

A Phase 1 clinical trial provides promising results for a broadly neutralizing antibody (bnAb) HIV vaccine, according to a new study. The findings of this first-in-humans test establish a clinical proof-of-principal for germline-targeting vaccine design for HIV and other intractable pathogens. A preventative HIV vaccine is urgently needed to put an end to the HIV/AIDS pandemic. One that elicits the production of broadly neutralizing antibodies (bnAbs), which can recognize the globally diverse strains of HIV and protect against infection, could provide an ideal solution. However, triggering bnAbs through vaccination has not yet been possible. One of the key challenges towards achieving this goal is that bnAbs rarely develop during infection, and, in humans, bnAb-precursor B cells are rather uncommon. An effective bnAb HIV vaccine will need to recruit rare bnAb precursors through germline-targeting to produce HIV bnAbs. Here, David Leggat and colleagues present results from a randomized, double-blind, placebo-controlled phase 1 clinical trial showing that a germline-targeting priming immunogen was safe and feasible, and induced bnAb-precursor responses in 26 of the 27 vaccine recipients (97%). Leggat et al. designed a germline-targeting, self-assembling nanoparticle immunogen, eOD-GT8, which presented 60 copies of an engineered HIV envelope protein containing mutations designed to enhance its affinity to recruit rare bnAb precursors. “The clinical trial reported by Leggat et al. provides persuasive human data supporting the concept of germline targeting,” writes Penny Moore in a related Perspective, which discusses the study’s findings and limitations in greater detail.

Expert Reaction

These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.

Associate Professor Clive Aspin is from the Faculty of Health at Te Herenga Waka Victoria University of Wellington

This is exciting news, especially for those people who have borne the brunt of the HIV pandemic – indigenous people, women, people in resource poor countries.

Now is the time for these researchers to be planning how this vaccine will reach these people and contribute to a reduction in the HIV disparities we see around the world, including in New Zealand and Australia where the indigenous peoples of both countries experience worse HIV outcomes than others.

The recruitment process for this study suggests the researchers need to build effective engagement with adversely affected communities to ensure that the vaccine roll-out achieves its maximum impact and reaches those communities that are in greatest need of a vaccine.

The science behind the development of this vaccine is important but just as important is the engagement with affected communities, especially those which have been most affected.

It is sobering to think that this clinical development has been 30+ years in the making and that scientists have devoted their entire careers to this approach. One would hope that the same amount of time and energy has gone into effective implementation once the breakthrough has occurred.

Last updated: 01 Dec 2022 12:06pm
Declared conflicts of interest:
None.

News for:

International

Media contact details for this story are only visible to registered journalists.